Physician profile
Daniel Perlow
NPI 1508568320
$878.17
in general payments reported to CMS, 2019-2025
13 companies · $507 in 2025
The $507 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $371 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $240.57 | 2024-2025 | Briviact, Rystiggo, Zilbrysq |
| Pfizer INC. | $103.06 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $101.02 | 2024-2025 | Wainua, Andexxa |
| Jazz Pharmaceuticals INC. | $82.50 | 2024 | |
| Sk Life Science, INC. | $64.24 | 2025 | |
| Novartis Pharmaceuticals Corporation | $62.67 | 2024 | |
| Genentech USA, INC. | $48.02 | 2025 | Ocrevus Zunovo, Enspryng |
| Takeda Pharmaceuticals U.S.A., INC. | $41.41 | 2025 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $34.56 | 2025 | Austedo Xr |
| Tg Therapeutics, INC. | $34.49 | 2024-2025 | |
| Amgen INC. | $27.60 | 2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $19.78 | 2025 | Ultomiris |
| Acadia Pharmaceuticals INC | $18.25 | 2025 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Perlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.